[
  {
    "ts": null,
    "headline": "S&P 500 Gains & Losses Today: Index Notches 5-Day Win Streak Despite Consumer Sentiment Slide",
    "summary": "The S&P 500 added 0.7% on Friday, May 16, 2025, closing the week with a fifth straight day of gains even as a survey showed sagging consumer sentiment.",
    "url": "https://finnhub.io/api/news?id=30622bd8a0dc4ea7a81c4e4c0c79e9fdbe2011dd84067ed9c52c684486ba1af6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747427756,
      "headline": "S&P 500 Gains & Losses Today: Index Notches 5-Day Win Streak Despite Consumer Sentiment Slide",
      "id": 134567824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The S&P 500 added 0.7% on Friday, May 16, 2025, closing the week with a fifth straight day of gains even as a survey showed sagging consumer sentiment.",
      "url": "https://finnhub.io/api/news?id=30622bd8a0dc4ea7a81c4e4c0c79e9fdbe2011dd84067ed9c52c684486ba1af6"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Moderna (MRNA) Stock?",
    "summary": "Back in 2024, on May 14, Mad Money’s Jim Cramer was asked about Moderna, Inc. (NASDAQ:MRNA), explaining that some family members had owned it during its run-up to $400 and that he was now considering buying it around $130. Cramer confirmed his long-standing belief in the stock back then, saying: “I’m a believer. I’ve been […]",
    "url": "https://finnhub.io/api/news?id=559716fdd5e45b8650a4de5396f8a8cf3c83b98f992973acf3536c290aea850a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747426690,
      "headline": "Was Jim Cramer Right About Moderna (MRNA) Stock?",
      "id": 134568140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Back in 2024, on May 14, Mad Money’s Jim Cramer was asked about Moderna, Inc. (NASDAQ:MRNA), explaining that some family members had owned it during its run-up to $400 and that he was now considering buying it around $130. Cramer confirmed his long-standing belief in the stock back then, saying: “I’m a believer. I’ve been […]",
      "url": "https://finnhub.io/api/news?id=559716fdd5e45b8650a4de5396f8a8cf3c83b98f992973acf3536c290aea850a"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (NasdaqGS:MRNA) Begins Phase 1 Study on Novel Cancer Therapy Candidate",
    "summary": "Moderna (NasdaqGS:MRNA) initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock experienced a 3% decline over the last week. This movement contrasts with broader market trends, as major indexes such as the S&P 500 and Nasdaq saw gains. Moderna's decline could have been moderated by these recent clinical developments amidst a rising market, emphasizing the complex interplay...",
    "url": "https://finnhub.io/api/news?id=6acedc5b2ed373332c70a421487e8934303e0ddef8bd0a02444ba93d7f9475bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747418443,
      "headline": "Moderna (NasdaqGS:MRNA) Begins Phase 1 Study on Novel Cancer Therapy Candidate",
      "id": 134568141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock experienced a 3% decline over the last week. This movement contrasts with broader market trends, as major indexes such as the S&P 500 and Nasdaq saw gains. Moderna's decline could have been moderated by these recent clinical developments amidst a rising market, emphasizing the complex interplay...",
      "url": "https://finnhub.io/api/news?id=6acedc5b2ed373332c70a421487e8934303e0ddef8bd0a02444ba93d7f9475bd"
    }
  },
  {
    "ts": null,
    "headline": "1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid",
    "summary": "Moderna's clinical progress and deep pipeline of mRNA candidates suggest a promising future.  Teladoc continues to lose market share in the competitive telehealth space -- a serious concern.  Let's consider one stock in each category: Moderna (NASDAQ: MRNA), a beaten-down stock with decent prospects, and Teladoc Health (NYSE: TDOC), one whose future looks dim.",
    "url": "https://finnhub.io/api/news?id=3db47b43426b039a261cdb00f32e92aaa166991efe8723c7f97d08ce3079aa4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747387800,
      "headline": "1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid",
      "id": 134499230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna's clinical progress and deep pipeline of mRNA candidates suggest a promising future.  Teladoc continues to lose market share in the competitive telehealth space -- a serious concern.  Let's consider one stock in each category: Moderna (NASDAQ: MRNA), a beaten-down stock with decent prospects, and Teladoc Health (NYSE: TDOC), one whose future looks dim.",
      "url": "https://finnhub.io/api/news?id=3db47b43426b039a261cdb00f32e92aaa166991efe8723c7f97d08ce3079aa4b"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Novel approach to HIV vaccine shows early promise",
    "summary": "The first human clinical trials testing a new strategy toprotect against HIV infections have yielded promising...",
    "url": "https://finnhub.io/api/news?id=04bb3a7e57019f2a22d37a25637437f0400e8cb3a465dbe70382ac337dafb6cb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747378884,
      "headline": "Health Rounds: Novel approach to HIV vaccine shows early promise",
      "id": 134496002,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "The first human clinical trials testing a new strategy toprotect against HIV infections have yielded promising...",
      "url": "https://finnhub.io/api/news?id=04bb3a7e57019f2a22d37a25637437f0400e8cb3a465dbe70382ac337dafb6cb"
    }
  }
]